[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-328502-105":59,"doc-detail-328502-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","emerging-role-of-mucins-in-antibody-drug-conjugates-for-ovarian-cancer-therapy","Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy","","Ovarian cancer is the deadliest gynecologic malignancy, largely driven by late diagnosis, early intraperitoneal spread, and frequent resistance to chemotherapy. Limited symptoms and insufficient screening contribute to advanced-stage detection and high mortality. Antibody-drug conjugates (ADCs) are presented as targeted biotherapeutics that deliver potent cytotoxic drugs to tumor- or metastasis-associated antigens via linker chemistry. Mucins including MUC16, MUC13, and MUC1 show elevated expression in ovarian tumors, offering promising ADC targets and potentially overcoming limitations of conventional markers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/emerging-role-of-mucins-in-antibody-drug-conjugates-for-ovarian-cancer-therapy/328502/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/emerging-role-of-mucins-in-antibody-drug-conjugates-for-ovarian-cancer-therapy/328502.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is ovarian cancer often diagnosed at advanced stages?","Question",{"text":112,"@type":113},"Early-stage ovarian cancer is frequently asymptomatic, and effective screening methods are lacking, leading to diagnosis in later phases.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What problem do ADCs aim to address in ovarian cancer therapy?",{"text":117,"@type":113},"ADCs are designed to deliver high-potency cytotoxic drugs directly to tumor-associated antigen targets, helping manage cancers that resist conventional chemotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"Which mucins are highlighted as promising ADC targets?",{"text":121,"@type":113},"MUC16, MUC13, and MUC1 are emphasized because they show significantly higher expression in ovarian tumors than in normal and/or benign samples.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},328502,1790013014,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Malik etal. Journal of Ovarian Research (2024) 17:161  \n[https://doi.org/10.1186/s13048-024-01485-2](https://doi.org/10.1186/s13048-024-01485-2)  \nJournal of Ovarian Research  \nREVIEW Open Access  \nEmerging role of mucins in antibody drug conjugates for ovarian cancer therapy  \nShabnam Malik 1,2, Mohammed Sikander 1,2, Natasha Bell2, Daniel Zubieta 1,2, Maria C. Bell3, Mural i M. Yallapu 1,2 and Subhash C. Chauhan 1,2*  \nAbstract  \nOvarian cancer stands as the deadliest gynecologic malignancy, responsible for nearly 65% of all gynecologic cancer-related deaths. The challenges in early detection and diagnosis, coupled with the widespread intraperitoneal spread of cancer cells and resistance to chemotherapy, contribute significantly to the high mortality rate of this disease. Due to the absence of specific symptoms and the lack of effective screening methods, most ovarian cancer cases are diagnosed at advanced stages. While chemotherapy is a common treatment, it often leads to tumor recurrence, necessitating further interventions. In recent years, antibody-drug conjugates (ADCs) have emerged as a valuable tool in targeted cancer therapy. These complex biotherapeutics combine an antibody that specifically targets tumor specific/associated antigen(s) with a high potency anti-cancer drug through a linker, offering a promising approach for ovarian cancer treatment. The identification of molecular targets in various human tumors has paved the way for the development of targeted therapies, with ADCs being at the forefront of this innovation. By delivering cytotoxic agents directly to tumors and metastatic lesions, ADCs show potential in managing chemo-resistant ovarian cancers. Mucins such as MUC16, MUC13, and MUC1 have shown significantly higher expression in ovarian tumors as compared to normal and/or benign samples, thus have become promising targets for ADC generation. While traditional markers are limited by their elevated levels in non-cancerous conditions, mucins offer a new possibility for targeted treatment in ovarian cancer. This review comprehensively described the potential of mucins for the generation of ADC therapy, highlighting their importance in the quest to improve the outcome of ovarian cancer patients.  \nKeywords Ovarian cancer, Antibody drug conjugate (ADC), Mucins, MUC1, MUC13, MUC16, FRα, NaPi2B, Mesothelin  \n*Correspondence:  \nSubhash C. Chauhan  \n[Subhash.Chauhan@utrgv.edu](Subhash.Chauhan@utrgv.edu)  \n1Division of Cancer Immunology and Microbiology, Medicine and Oncology Integrated Service Unit, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA  \n2South Texas Center of Excellence in Cancer Research (ST-CECR), McAllen, TX 78504, USA  \n3Sanford Health, Sanford Gynecologic Oncology Clinic, Sioux Falls,  \nSD 57104, USA  \nIntroduction  \nOvarian cancer (OC), known as the deadliest gynecologic malignancy, remains a formidable threat to women’s health worldwide, constituting a significant proportion of cancer-related fatalities [1, 2]. Often asymptomatic in its early stages, ovarian cancer tends to be diagnosed at an advanced phase, contributing to its alarming fatality rates among gynecological cancers [3]. In the United States, it stands as a major contributor to cancer-related deaths in women, underscoring the critical need for improved screening, early detection methods, and advancements in treatment modalities [4]. In addition, the Global Cancer  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of","cbCaiclcV5txg971","https://ap.wps.com/l/cbCaiclcV5txg971","pdf",2221073,12,"English","# Abstract\n# Introduction\n## Epidemiology, diagnosis, and prognosis\n## Current treatments and chemotherapy resistance\n## Rationale for targeted therapy and ADC development","[{\"question\":\"Why is ovarian cancer often diagnosed at advanced stages?\",\"answer\":\"Early-stage ovarian cancer is frequently asymptomatic, and effective screening methods are lacking, leading to diagnosis in later phases.\"},{\"question\":\"What problem do ADCs aim to address in ovarian cancer therapy?\",\"answer\":\"ADCs are designed to deliver high-potency cytotoxic drugs directly to tumor-associated antigen targets, helping manage cancers that resist conventional chemotherapy.\"},{\"question\":\"Which mucins are highlighted as promising ADC targets?\",\"answer\":\"MUC16, MUC13, and MUC1 are emphasized because they show significantly higher expression in ovarian tumors than in normal and/or benign samples.\"}]","Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy | PDF",1789979994]